Instem (INS)

 

INS Share PerformanceMore

52 week high328.55 26/09/16
52 week low156.00 21/08/17
52 week change -74.00 (-31.62%)
4 week volume58,895 27/07/17

Media for (INS)

Presenter: Phil Reason, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity, TVRs & PDMR Dealing

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Payment of consideration and total voting rights

Notification of a change in the total number of voting rights

Holding(s) in Company

Notification of major interests in shares

All resolutions passed at AGM of Instem

Instem has announced that, at its Annual General Meeting held earlier today, all resolutions were passed. At 2:59pm: (LON:I...

Result of AGM

Notification of the result of any voting at an AGM

Holding(s) in Company

Notification of major interests in shares

US Government Contract

Statement regarding a contract entered into/awarded/signed

Instem schedules AGM

Instem will hold its annual general meeting at the offices of RSM, 3 Hardman Street, Manchester, M3 3HF, on 18 May at 10...

Fundamental DataMore

P/E ratio23.188
EPS6.9
Dividend yield0 %

Equity Research (INS)

progressive research
Instem plc
13/04/2017
Instem’s FY 16A results were line with the Jan-17 trading update and our forecasts. Excluding the Clinical business, performance remains solid, particularly in pre-clinical and the SEND businesses....
progressive research
Instem plc
16/01/2017
Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown...
progressive research
Instem plc
21/12/2016
Instem recently confirmed that its Instem Clinical business continues to be impacted by a slowdown in the early-phase clinical market and, despite other areas of Instem performing well, that this...

Latest discussion posts More

  • NEW ARTICLE: Instem worth 24% more

    "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...
    19-Sep-2016
    II Editor

Users' HoldingsMore

Users who hold Instem also hold..
VECTURA40%
BT GROUP40%
AMEC FOSTER40%
GLAXOSMITHKLINE40%
RDS 'B'30%

Codes & Symbols

ISINGB00B3TQCK30
SymbolsINS, LSE:INS, INS.L, INS:LN, LON:INS, XLON:INS